Gsk (GLAXF) Short term Debt (2016 - 2025)

Gsk's Short term Debt history runs 10 years deep, the most recent figure standing at $4.0 billion for Q4 2025.

• In Q4 2025, Short term Debt rose 32.89% year-over-year to $4.0 billion; the TTM figure through Dec 2025 stood at $4.0 billion (up 32.89% YoY), while the FY2025 annual figure was $4.0 billion, up 32.26% from the prior year.
• Short term Debt was $4.0 billion for Q4 2025 at Gsk, up from $3.0 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $4.0 billion in Q4 2025 to a low of $1.3 billion in Q4 2021.
• Historically, Short term Debt has averaged $2.7 billion across 5 years, with a median of $3.0 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Short term Debt jumped 129.86% in 2023, then retreated 13.24% in 2024.
• A 5-year view of Short term Debt shows it stood at $1.3 billion in 2021, then advanced by 17.08% to $1.5 billion in 2022, then soared by 129.86% to $3.5 billion in 2023, then retreated by 13.24% to $3.0 billion in 2024, then jumped by 32.89% to $4.0 billion in 2025.
• The last three Short term Debt figures came in at $4.0 billion (Q4 2025), $3.0 billion (Q4 2024), and $3.5 billion (Q4 2023), per Business Quant data.